Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A study led by researchers from the University of Oxford’s Big Data Institute has identified 25 genetic variants linked to infertility and 269 that are linked to hormones that can affect fertility.

DNA double helix

The study, published in Nature Genetics, is the first comprehensive view of the relationships between genes and infertility. The results may lead to improved diagnosis and treatments for fertility-related conditions.

Infertility, defined as the inability to achieve pregnancy within 12 months of regular unprotected sexual intercourse, is thought to affect one in six couples around the world. It is associated with a wide range of social, environmental, and genetic factors but the exact cause is not known for up to 28% of couples and 40% of women.

Previous studies have suggested that infertility may be caused by problems with reproductive hormones and obesity but so far there has been limited evidence on how our genes affect fertility.

Key findings:

  • 25 genetic variants for infertility were identified, 22 in women and three in men;
  • 269 genetic variants were found to be associated with hormones that can affect fertility, including follicle-stimulating hormone (which has different functions depending on sex and age), luteinising hormone (which triggers ovulation in women and sperm production in men), oestradiol (the main oestrogen found in women), and testosterone. However, no genetic association was found between female infertility and reproductive hormones;
  • Three genetic variants were found to be associated with male infertility. One of the three variations is near ENO4, a gene linked to sperm movement. When this gene is removed in male mice, it causes infertility.

 

Read the full story on the Nuffield Department of Population Health website.

 

Similar stories

First clinical study in GSK-Oxford Experimental Medicine Collaboration starts as first patient dosed in ulcerative colitis experimental trial

The first patient in the PEGASUS clinical study, part of the GSK-University of Oxford Experimental Medicine Collaboration, received the first dose last week, on 8 October 2026.

Wearable chest patch could support hospital-level care at home, study finds

Researchers in Oxford have shown that wearable chest patches can be used to effectively monitor vital signs in many acutely unwell patients receiving hospital-level care in their own homes.

Brain immune cells protect neurons in Parkinson’s disease by “nibbling” harmful material

New research, published in Science Translational Medicine, reveals how a specialised population of the brain’s immune cells can remove harmful protein clumps from nerve cells (neurons), pointing to potential new treatments for Parkinson’s disease.

Phase I clinical study of ChAdOx1 BDBV vaccine launches in Uganda

The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine (MRC/UVRI & LSHTM Uganda Research Unit) has launched a Phase I clinical study evaluating the safety and immunogenicity of a candidate vaccine against Bundibugyo virus disease (BVD), a severe form of Ebola virus disease caused by Bundibugyo virus (BDBV), in partnership with the University of Oxford.

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.